JMP Securities Downgrades Pardes Biosciences to Market Perform
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Roy Buchanan has downgraded Pardes Biosciences (NASDAQ:PRDS) from Market Outperform to Market Perform.
July 18, 2023 | 9:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pardes Biosciences has been downgraded by JMP Securities from Market Outperform to Market Perform.
The downgrade by JMP Securities from Market Outperform to Market Perform indicates a less optimistic outlook for Pardes Biosciences. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100